Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)

Giorgio Cocconi, Maurizio Tonato, Francesco di Costanzo, Giancarlo Bisagni, Virginio Belsanti, Franco Buzzi, Guido Ceci

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Twenty-four evaluable extensively pretreated advanced breast cancer patients received a combination of platinum and etoposide. Platinum was given i.v. at the dose of 80 mg/mq at day 1. Etoposide was given at the dose of 120 mg/mq i.v. at day 1, and p.o. at the dose of 200 mg/mq at day 3 and 5. Treatment was repeated every 3 weeks. CR was never obtained. PR was observed in four patients (17%), MR in two, NC in seven and PD in 11 patients. PR plus MR occurred in six patients (25%). Considering the extensive pretreatment of patients, the results seem to indicate that this combination is active and can be included among the possible options in treating chemotherapy refractory advanced breast cancer. Moreover, it deserves further evaluation in an earlier phase of the disease.

Original languageEnglish
Pages (from-to)761-764
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume22
Issue number7
DOIs
Publication statusPublished - 1986

Fingerprint

Medical Oncology
Etoposide
Platinum
Breast Neoplasms
Drug Therapy
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.). / Cocconi, Giorgio; Tonato, Maurizio; di Costanzo, Francesco; Bisagni, Giancarlo; Belsanti, Virginio; Buzzi, Franco; Ceci, Guido.

In: European Journal of Cancer and Clinical Oncology, Vol. 22, No. 7, 1986, p. 761-764.

Research output: Contribution to journalArticle

Cocconi, Giorgio ; Tonato, Maurizio ; di Costanzo, Francesco ; Bisagni, Giancarlo ; Belsanti, Virginio ; Buzzi, Franco ; Ceci, Guido. / Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.). In: European Journal of Cancer and Clinical Oncology. 1986 ; Vol. 22, No. 7. pp. 761-764.
@article{51127fe9242340ef85432395394f6910,
title = "Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)",
abstract = "Twenty-four evaluable extensively pretreated advanced breast cancer patients received a combination of platinum and etoposide. Platinum was given i.v. at the dose of 80 mg/mq at day 1. Etoposide was given at the dose of 120 mg/mq i.v. at day 1, and p.o. at the dose of 200 mg/mq at day 3 and 5. Treatment was repeated every 3 weeks. CR was never obtained. PR was observed in four patients (17{\%}), MR in two, NC in seven and PD in 11 patients. PR plus MR occurred in six patients (25{\%}). Considering the extensive pretreatment of patients, the results seem to indicate that this combination is active and can be included among the possible options in treating chemotherapy refractory advanced breast cancer. Moreover, it deserves further evaluation in an earlier phase of the disease.",
author = "Giorgio Cocconi and Maurizio Tonato and {di Costanzo}, Francesco and Giancarlo Bisagni and Virginio Belsanti and Franco Buzzi and Guido Ceci",
year = "1986",
doi = "10.1016/0277-5379(86)90360-3",
language = "English",
volume = "22",
pages = "761--764",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian oncology group for clinical research (G.O.I.R.C.)

AU - Cocconi, Giorgio

AU - Tonato, Maurizio

AU - di Costanzo, Francesco

AU - Bisagni, Giancarlo

AU - Belsanti, Virginio

AU - Buzzi, Franco

AU - Ceci, Guido

PY - 1986

Y1 - 1986

N2 - Twenty-four evaluable extensively pretreated advanced breast cancer patients received a combination of platinum and etoposide. Platinum was given i.v. at the dose of 80 mg/mq at day 1. Etoposide was given at the dose of 120 mg/mq i.v. at day 1, and p.o. at the dose of 200 mg/mq at day 3 and 5. Treatment was repeated every 3 weeks. CR was never obtained. PR was observed in four patients (17%), MR in two, NC in seven and PD in 11 patients. PR plus MR occurred in six patients (25%). Considering the extensive pretreatment of patients, the results seem to indicate that this combination is active and can be included among the possible options in treating chemotherapy refractory advanced breast cancer. Moreover, it deserves further evaluation in an earlier phase of the disease.

AB - Twenty-four evaluable extensively pretreated advanced breast cancer patients received a combination of platinum and etoposide. Platinum was given i.v. at the dose of 80 mg/mq at day 1. Etoposide was given at the dose of 120 mg/mq i.v. at day 1, and p.o. at the dose of 200 mg/mq at day 3 and 5. Treatment was repeated every 3 weeks. CR was never obtained. PR was observed in four patients (17%), MR in two, NC in seven and PD in 11 patients. PR plus MR occurred in six patients (25%). Considering the extensive pretreatment of patients, the results seem to indicate that this combination is active and can be included among the possible options in treating chemotherapy refractory advanced breast cancer. Moreover, it deserves further evaluation in an earlier phase of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0022528943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022528943&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(86)90360-3

DO - 10.1016/0277-5379(86)90360-3

M3 - Article

C2 - 3770033

AN - SCOPUS:0022528943

VL - 22

SP - 761

EP - 764

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -